Twist Biosciences and Agilent Settle Dispute, Avoid Costly Trial

A trial to resolve Agilent's (NYSE:A) dispute with biotech company Twist Biosciences (NASDAQ:TWST) won't begin on Feb. 24 after all. Instead, Twist is paying $22.5 million to settle -- without admission of wrongdoing -- litigation alleging breach of contract, breach of duty of loyalty, and alleged misappropriation of trade secrets by Twist's management, including CEO and co-founder Emily Leproust, a former Agilent employee.